Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit.

Abstract

Palivizumab is currently licensed for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children with chronic lung disease, with a history of preterm birth, or with haemodynamically significant congenital heart disease, but its routine use during outbreaks in neonatal intensive care units (NICUs) is not… (More)
DOI: 10.1016/j.jhin.2010.01.013

Topics

  • Presentations referencing similar topics